Furthermore, XIAP induces resistance to tyrosine kinase inhibitors such as Lapatinib in breast cancer (Aird et al., 2010), and Imatinib in acute myeloid leukemia (AML) (Silva et al., 2013). This evidence concerns the gene XIAP and breast cancer.